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J. Bridgewater 11, D. Propper12, R. Gillmore13, A. Gopinathan2, R. Skells1, P. Bundi1, R. Brais1, K. Dalchau1, L. Bax1, A. Chhabra1,
A. Machin1, A. Dayim1, K. McAdam14, S. Cummins15, L. Wall16, R. Ellis17, A. Anthoney18, J. Evans19, Y. T. Ma20, C. Isherwood2, A. Neesse21,
D. Tuveson22 and D. I. Jodrell1,2
BACKGROUND: Nab-paclitaxel plus gemcitabine (nabP+gemcitabine) offers modest survival gains for patients with metastatic
pancreatic ductal adenocarcinoma (PDAC). Sequential scheduling of nabP+gemcitabine in a PDAC mouse model improved
efficacy; this hypothesis was tested in a clinical trial.
METHODS: Patients with previously untreated metastatic PDAC were randomised to receive nabP+gemcitabine administered
either concomitantly on the same day, or sequentially, with gemcitabine administered 24 h after nabP. The primary outcome
measure was progression-free survival (PFS). Secondary outcome measures were objective response rate (ORR), overall survival (OS),
safety, quality of life (QoL) and predictive biomarkers.
RESULTS: In total, 71 patients received sequential (SEQ) and 75 concomitant (CON) treatment. Six-month PFS was 46% with SEQ
and 32% with CON scheduling. Median PFS (5.6 versus 4.0 months, hazard ratio [HR] 0.67, 95% confidence interval [95% CI]
0.47–0.95, p= 0.022) and ORR (52% versus 31%, p= 0.023) favoured the SEQ arm; median OS was 10.2 versus 8.2 months (HR 0.93,
95% CI 0.65–1.33, p= 0.70). CTCAE Grade ≥3 neutropaenia incidence doubled with SEQ therapy but was not detrimental to QoL.
Strongly positive tumour epithelial cytidine deaminase (CDA) expression favoured benefit from SEQ therapy (PFS HR 0.31, 95% CI
0.13–0.70).
CONCLUSIONS: SEQ delivery of nabP+gemcitabine improved PFS and ORR, with manageable toxicity, but did not significantly
improve OS.
CLINICAL TRIAL REGISTRATION: ISRCTN71070888; ClinialTrials.gov (NCT03529175).
British Journal of Cancer https://doi.org/10.1038/s41416-020-0846-2
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is the leading cause of
cancer mortality.1 Without surgery, PDAC is almost uniformly
lethal; however, most patients present with unresectable disease.
The median overall survival (OS) of patients with metastatic PDAC
is under 1 year, even with optimal chemotherapy. The registration
MPACT trial established nab-Paclitaxel (nabP) combined with
gemcitabine as a standard first-line treatment for patients with
metastatic PDAC, reporting improved median OS of 8.7 months
for the combination compared with 6.6 months for gemcitabine
alone (p= 0.001).2,3
The mechanism by which nabP enhances gemcitabine efficacy
is uncertain. PDAC is a stromal-rich tumour expressing high
amounts of secreted protein acidic and rich in cysteine (SPARC).
SPARC may act as an albumin-binding protein capable of
sequestering nabP to concentrate the drug intra-tumourally. Initial
exploration in mice xenografts and PDAC patients treated with
nabP indicated drug-induced stromal depletion, which may
facilitate gemcitabine delivery to the tumour.4,5 However, studies
in the KPC genetically engineered mouse model reported that
genetic ablation of SPARC did not change intra-tumoural nabP
concentrations.6,7 In the KPC model, nabP induced reactive
oxygen species (ROS) that led to decreases in cytidine deaminase
(CDA), a key intracellular enzyme that inactivates gemcitabine.
Rapid inactivation of gemcitabine could explain limited antitu-
mour efficacy of gemcitabine in patients with PDAC.8,9
The standard treatment schedule of nabP+gemcitabine is to
administer gemcitabine to the patient immediately after nabP on
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days 1, 8 and 15 of a 28-day cycle. Both drugs are given as 30-min
infusions. Inhibition of CDA by ROS-mediated degradation
demonstrated in the KPC mouse model suggested that sequential
administration of nab-paclitaxel and gemcitabine might further
increase intra-tumoural gemcitabine concentrations and hence
provide a means of enhancing antitumour activity.6
The SIEGE (Scheduling nab-paclitaxel with gemcitabine) rando-
mised phase II trial was therefore designed to evaluate whether
administration of nabP 24 h in advance of gemcitabine might
confer a therapeutic benefit. The MPACT registration trial did not
collect quality-of-life (QoL) data from recruited patients, and since
SEQ delivery increased the burden of hospital visits for patients,
the SIEGE trial included formal evaluation of patient QoL
associated with both standard CON and experimental SEQ
treatment delivery, using validated questionnaires. To explore
the biological rationale for SEQ scheduling in clinical practice,
blood and tumour samples were collected from all patients, and
both CDA and tumour stromal content were evaluated as
potential predictors of treatment outcome.
METHODS
Patients
Patients aged ≥18 years with histologically-, or cytologically
confirmed stage 4 PDAC and previously untreated, measurable
metastatic disease, with a Karnofsky performance status (KPS) ≥
70% were eligible for this trial. Other inclusion criteria included
haemoglobin ≥100 g/L, platelets ≥100 × 109/L, white blood cell
count ≥3 × 109/L, aspartate aminotransferase and/or alanine
aminotransferase ≤2.5 × upper limit of normal (ULN), bilirubin
<1.5 × ULN and creatinine ≤1.5 × ULN. The SIEGE trial protocol
(ISRCTN71070888) was approved by the Northern Ireland Research
Ethics Committee3 and was performed in accordance with the
Declaration of Helsinki and the EU Clinical Trials Directive 2001/20/
EC. All patients provided written informed consent. Grant funding
for this investigator-initiated trial was provided by Celgene Sarl.
The funder had no role in study design, data collection, analysis,
interpretation or writing of the report.
Treatment
Patients were randomised 1:1 using a random block method to
receive 6 cycles of 4-weekly nabP+gemcitabine, administered either
concomitantly (nabP 125mg/m2, 30min of IV infusion immediately
followed by gemcitabine, 1000mg/m2 IV infusion on days 1, 8 and 15
of a 28-day cycle), or sequentially: the same regimen, but
gemcitabine administered on days 2, 9 and 16, starting 24 h after
commencing nabP. Primary prophylaxis with growth factor (GCSF)
support was not mandated. Patients benefiting from treatment could
continue beyond 6 cycles at the investigator’s discretion.
Procedures
Patients were assessed clinically prior to randomisation and at the
start of each treatment cycle, then 4-weekly until disease
progression and then 3-monthly. Adverse events (AEs) were
recorded for up to 30 days after stopping treatment using NCI
CTCAE version 4.03. Quality of life (QoL) was assessed using the
EORTC QLQ-C30 and QLQ-PAN26 questionnaires at each assess-
ment visit until 12 months. Imaging was performed at baseline
and every 8 weeks until disease progression to assess objective
response rate (ORR), using RECIST version 1.1. Central radiology
retrospective review of RECIST response assessments was planned
for 10% of recruited patients. Provision of a pre-treatment tumour
biopsy within 12 weeks of randomisation was mandatory.
Research blood samples to measure CDA activity were collected
pre-randomisation, prior to treatment on day 1 of each cycle, on
days 8 and 15 of cycle 1 and at the time of disease progression.
Additional samples were collected on days 2, 9 and 16 of cycle 1
for patients allocated sequential therapy.
Cytidine deaminase (CDA) functional assay
CDA activity was measured in whole blood by a spectrophoto-
metric assay, as previously described.10 In brief, CDA releases
ammonium during the deamination of cytidine. Therefore, whole-
blood samples were diluted 1:10 with water and incubated
overnight with cytidine substrate. The concentration of released
ammonium was measured using spectrophotometry at 630 nM
after coupling with phenol. Protein concentrations were quanti-
fied in whole-blood samples diluted 1:200 with water, using the
Merck Millipore Direct Detect assay. CDA activity was presented as
enzyme activity per milligram of protein (UA/mg).
Histological assessment of tumour samples
Tumour samples were assessed histologically by a single specialist
pathologist on standard H&E sections. Tumour samples were
assessed for tumour content, grade and the presence of
associated tumour stroma (defined as none, minimal, moderate
or extensive). Immunohistochemistry (IHC) for CDA was performed
using a commercial polyclonal antibody (Abcam, ad137605)
diluted to 1:400. CDA expression was evaluated in both the
tumour epithelium and stromal components. For the latter, only
stromal spindle cells (representing stromal fibroblasts and
myofibroblasts) were evaluated; extracellular constituents such
as necrosis, mucin, oedema, haemorrhage and any chronic
inflammatory infiltrate were specifically excluded. CDA expression
scoring of each of the tumour components (epithelial and stromal
cells) were as follows: no staining (negative), focal weak staining
(weakly positive), diffuse weak or focal strong staining (positive),
diffuse strong staining (strongly positive) or unknown if there was
insufficient tumour for assessment.
Statistical analysis
The primary outcome measure was progression-free survival (PFS).
Secondary outcome measures were ORR, OS, safety and QoL. An
exploratory analysis was performed to identify potential predictive
biomarkers. With 5% significance and 90% power, 55 patients
were required to detect a 6-month PFS rate of ≤25% versus ≥44%
(or a median PFS of ≤3 months versus ≥5 months) in each arm.
Allowing for 25% non-evaluable patients, 146 patients were
required. Evaluable patients had to receive at least two cycles of
planned treatment with both drugs administered for at least two
out of the three planned treatment days in each cycle. Primary
analysis was by Kaplan–Meier estimates of 6-month PFS rate and
median PFS for each of 2 arms for all patients randomised. The
log-rank test was applied to compare PFS and OS between arms;
response was compared using the Chi-squared test. The same
analysis was repeated for evaluable patients. The subscales of
EORTC QLQ-C30 and QLQ-PAN26 questionnaires were derived
according to standard-scoring manuals, and the scores were
standardised to a range of 0–100. Clinically important differences
were categorised as small if the mean score change was 5–10
points, moderate for 10–20 points and large for >20 points.11
Analyses of changes from baseline over time and difference
between the 2 arms for subscales were carried out with repeated
measures using ANCOVA, adjusting for baseline level.
Biomarker outcomes were analysed in an exploratory manner.
The Pearson and Spearman correlation coefficient, Wilcoxon/
Kruskal–Wallis and regression models were applied to explore the
correlation between pre-treatment CDA activity and patient
characteristics (age, gender, KPS, site of primary tumour, liver
metastases, serum carbohydrate antigen 19.9 (CA19.9), C-reactive
protein (CRP) and neutrophil count). Descriptive statistics for CDA
activity in all samples associated with cycle 1 in both arms were
undertaken and depicted graphically to assess the impact of CDA
activity on CON versus SEQ scheduling. CDA activity in both arms
was measured on cycle 1 day 1, day 8, day 15 as well as on day 1
of cycles 2, 4 and 6 and compared using the Wilcoxon test. In the
SEQ arm, differences in CDA activity measured in cycle 1 on days 1
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and 2, days 8 and 9 and days 15 and 16 were evaluated using the
Wilcoxon test to establish changes after 24-h exposure to nabP.
Boxplots of pre-treatment CDA by ORR and CTCAE grade were
generated and the Kruskal–Wallis test applied. Cox regression
models were applied to assess the predictive value of CDA for PFS
and OS.
Distributions and frequencies of tumour grade, CDA expression
and stroma content by IHC, and their correlation with PFS and OS,
were analysed for each of the treatment arms, as well as for all
study patients. Kaplan–Meier plots were generated for each of the
treatment arms and for all study patients, by tumour grade, CDA
expression and stroma content. Hazard ratios were estimated
using Cox regression models.
RESULTS
Patients and treatment delivery
From March 2014 to March 2016, 146 patients (75 concomitant
[CON] arm, 71 sequential [SEQ] arm) were recruited at 19 UK centres
(Trial Flow Diagram is provided in Supplementary Fig. S1). Patient
demographics and pre-treatment disease characteristics were well
balanced between the two arms (Table 1). Median patient age was
66 years, 43% were female and 62% had KPS > 90%.
The median (range) number of nabP+gemcitabine chemother-
apy cycles received was 3 (0–12) in the CON arm and 4 (0–24) in
the SEQ arm. In the SEQ arm, a 24+ /− 2-h interval between nabP
and gemcitabine administration was achieved in 94% of 828
treatment administrations. Twenty-one (28%) patients in the CON
and 30 (42%) patients in the SEQ arm completed ≥6 cycles of
planned treatment. The most common reasons for patients
stopping treatment sooner were AEs (20 CON versus 22 SEQ
arm patients) and progressive disease (23 CON versus 11 SEQ arm
patients). Thirty-eight (26%) patients received second-line che-
motherapy (22 CON versus 16 SEQ arm patients).
Toxicity
Four patients who were randomised did not start chemotherapy:
1 CON arm patient progressed rapidly and died within 1 month of
enrolment; 2 SEQ arm patients withdrew consent; 1 SEQ arm
patient was subsequently found to be ineligible. Therefore, safety
analysis was based on 142 patients. The incidence of any AE in
both arms was similar, but severity was higher overall in the SEQ
arm (Table 2). Grade ≥3 AEs were reported in 61 (82%) patients
(average 0.69/cycle) in the CON arm, but in 66 (97%) patients
(average 0.87/cycle) in the SEQ arm. SEQ treatment was associated
with a higher incidence of grade ≥3 neutropaenia (24 CON versus
40 SEQ arm), although febrile neutropaenia rates were similar
(9 CON versus 11 SEQ arm). GCSF was administered to 12 (16%)
patients in the CON arm and 24 (35%) patients in the SEQ arm as
secondary prophylaxis.
The dose intensity of both nabP and gemcitabine was 17%
lower in the SEQ arm: the median dose per 4-week cycle in the
CON and SEQ arms, respectively, was 300mg/m2 versus 249 mg/
m2 for nabP and 2400mg/m2 versus 2000mg/m2 for gemcitabine.
The total cumulative dose of both nabP and gemcitabine was,
however, higher in the SEQ arm: median total dose per patient for
nabP and gemcitabine was 750mg/m2 and 6290mg/m2 in the
CON arm and 984mg/m2 and 7470mg/m2 in the SEQ arm,
consistent with longer treatment duration with SEQ delivery. Rates
of radiologically confirmed pneumonitis were low overall: 3
patients in each arm. Rates of peripheral neuropathy were similar
(22 CON and 22 SEQ arm patients) and grade 1–2 in all cases,
except 5 patients who experienced grade 3 events (2 CON and 3
SEQ arm). Seven deaths were attributed to treatment: 3 CON
arm (2 pneumonia and 1 febrile neutropaenia) and 4 SEQ arm
(1 pneumonitis, 1 colitis, 1 hypoxia and 1 febrile neutropaenia).
Efficacy
Local assessment of radiological response was undertaken in 117
(80% of total recruited) patients: 61 in the CON and 56 in the SEQ
arm. Central radiology review of local RECIST assessment was
performed in 11 randomly selected patients for whom at least 1
response assessment was performed and showed high concor-
dance in assessment of measurable target lesions. ORR was higher
with SEQ therapy: 29/56 (52%) versus 19/61 (31%) evaluable
patients experienced a complete or partial response (p= 0.023,
Supplementary Table S1).
With a median follow-up of 21.4 months, 133 (70 CON and 63
SEQ arm) patients had progressed or died, and 123 (64 CON and
59 SEQ arm) patients had died. The 6-month and median PFS were
32% (95% CI 21–43%) and 4.0 months (95% CI 3.0–5.4 months) in
the CON arm and 46% (95% CI 34–58%) and 5.6 months (95% CI
3.6–7.2 months) in the SEQ arm (HR 0.67 favouring the SEQ
schedule, 95% CI 0.47–0.95, p= 0.022) (Fig. 1a). The median OS
was 8.2 months (95% CI 6.1–10.0 months) in the CON arm versus
10.2 months (95% CI 6.3–11.5 months) in the SEQ arm (HR 0.93,
95% CI 0.65–1.33, p= 0.70) (Fig. 1b). For evaluable patients,
survival benefits with SEQ therapy appeared greater, although OS
still did not meet statistical significance: PFS HR 0.60 (95% CI
0.40–0.90, p= 0.014) and OS HR 0.83 (95% CI 0.54–1.28, p= 0.40)
(Fig. 1c, d; Supplementary Table S2).
Table 1. Patient pre-treatment characteristics.
CON (n= 75) SEQ (n= 71)
Age
Median (range) 67 (48, 82) 63 (45, 77)
Gender
Male 40 (53%) 43 (61%)
Female 35 (47%) 28 (39%)
Karnofsky performance status
100 17 (23%) 18 (25%)
90 33 (44%) 22 (31%)
80 19 (25%) 20 (28%)
70 6 (8%) 11 (15%)
ECOG performance status
0 33 (44%) 30 (43%)
1 38 (51%) 39 (56%)
2 4 (5%) 1 (1%)
Unknown 0 1
Site of primary tumour
Head 35 (47%) 34 (48%)
Body 19 (25%) 20 (28%)
Tail 21 (28%) 17 (24%)
Liver metastases
No 13 (17%) 11 (15%)
Yes 62 (83%) 60 (85%)
CA19.9 (U/ml)
Median (range) 4032 (1.0, 275228) 2377 (4.0, 217920)
<ULN 9 (13%) 9 (13%)
≥ULN 59 (87%) 60 (87%)
Unknown 7 2
C-reactive protein (mg/l)
Median (range) 9.0 (0.8, 249) 11.0 (0.3, 208)
Unknown 5 1
Neutrophil count (109/l)
Median (range) 5.3 (1.6, 19.3) 6.1 (2.6, 22.4)
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Table 2. Summary of Grade > 3 CTCAEs occurring in at least 5% patients.
CON (n= 74) SEQ (n= 68)
Grade 3, Grade 4, Grade 5, Grade 3, Grade 4, Grade 5,
n % n % n % n % n % n %
No. of patients experiencing worst-grade AEs 44 59 12 16 5 7 29 43 27 40 10 15
Fatigue 15 20 0 0 0 0 16 24 0 0 0 0
Neutrophil count decreased 20 27 4 5 0 0 19 28 21 31 0 0
Nausea 2 3 0 0 0 0 6 9 0 0 0 0
Diarrhoea 4 5 0 0 0 0 6 9 0 0 0 0
Anaemia 4 5 0 0 0 0 8 12 0 0 0 0
Vomiting 8 11 0 0 0 0 5 7 0 0 0 0
Abdominal pain 4 5 0 0 0 0 3 4 0 0 0 0
Platelet count decreased 7 9 1 1 0 0 2 3 1 1 0 0
White blood cell decreased 1 1 2 3 0 0 4 6 2 3 0 0
Lung infection 4 5 0 0 3 4 4 6 0 0 2 3
Febrile neutropaenia 6 8 2 3 1 1 7 10 3 4 1 1
GGT increased 5 7 2 3 0 0 2 3 1 1 0 0
Alanine aminotransferase increased 2 3 0 0 0 0 5 7 1 1 0 0
Thromboembolic event 2 3 0 0 0 0 4 6 0 0 1 1
Bilirubin increased 1 1 0 0 0 0 8 12 0 0 0 0
Sepsis 0 0 5 7 0 0 0 0 4 6 2 3
Dehydration 3 4 0 0 0 0 5 7 0 0 0 0
Hypotension 3 4 0 0 0 0 4 6 0 0 0 0
Other grade 5 AEs 1 gallbladder obstruction 1 pneumonitis, 1 colitis, 1 hypoxia and 1
cholangitis
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Fig. 1 Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS). a, c PFS and (b, d) OS for intention-to treat (a, b)
and evaluable (c, d) patients.
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Quality of life
A total of 523 QoL questionnaires were returned by 141 (97%)
patients (72 CON and 69 SEQ arm) during the course of this trial:
138 (95%) recruited patients (70 CON and 68 SEQ arm) completed
baseline EORTC QLQ-C30 and PAN26 questionnaires. The number
of questionnaires returned fell over time, as expected, although
returns were consistently higher in the SEQ arm: 79 (39 CON
and 40 SEQ) at 12 weeks, 59 (26 CON and 33 SEQ) at 26 weeks, 45
(17 CON and 28 SEQ) at 39 weeks and 17 (5 CON and 12 SEQ) at
52 weeks. The mean pre-treatment global health status score from
the QLQ-C30 questionnaire on a scale of 0–100 was 62 (63 for
the CON and 61 for the SEQ arm). Global health status scores
were overall stable over time (i.e. changes from baseline were less
than 5 points) and similar in both arms, with the exception of a
small deterioration of >5 points in the CON arm at 26 weeks
(Fig. 2a).
Since relatively few QoL assessments were available at later time
points, comparisons between the two arms mainly focused on the
first 26 weeks. The mean scores at baseline and changes from
baseline at 12 and 26 weeks of all QoL subscales derived from the
EORTC QLQ-C30 and PAN26 questionnaires were similar for the two
arms. For both trial arms, physical, role and social functioning
recorded by the QLQ-C30 questionnaire worsened over time, while
emotional functioning showed slight improvement (Fig. 2b). For
specific symptoms (Fig. 2c), treatment appeared to improve pain,
pancreatic pain, insomnia, appetite and constipation. The gains were
generally less evident at 26 weeks compared with 12 weeks.
Treatment was associated with an increase in breathlessness, altered
bowel habit and to a lesser extent worsening perceptions of body
image and sexuality. Again, all these symptoms were less apparent
at 26 weeks compared with 12 weeks. There were 2 statistically
significant differences from baseline levels identified between the 2
trial arms, both favouring SEQ therapy: better appetite at 12 weeks
(p= 0.047) and less change in bowel habit at 26 weeks (p= 0.003).
Breathlessness at week 26 was reported to be more severe in the
CON arm, although the difference between the two arms did not
reach statistical significance (p= 0.065). More detailed breakdown of
QoL data is provided in Supplementary Table S3.
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Fig. 2 Changes from baseline in EORTC QLQ-C30 QoL scores associated with treatment. a Global health status (b) QoL subscales
(c) symptoms.
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Whole-blood CDA activity
Pre-treatment whole-blood CDA activity (measured pre- and
repeated post randomisation), with time intervals between
samples ranging 0–26 days, showed similar mean (14.0 and 14.3
UA/mg, respectively) and median (11.5 and 11.9 UA/mg, respec-
tively) values, as well as low intra-patient variability (coefficient of
variation= 18%). For subsequent analyses, the mean value of pre-
treatment CDA activity measurements was used as the baseline
CDA activity.
Baseline whole-blood CDA activity correlated with neutrophil
count for the whole-trial population (correlation coefficient 0.82, p
< 0.0001, Supplementary Table S4, Supplementary Fig. S2) after
adjusting for other baseline patient characteristics, but did not
predict for ORR (Fig. 3a), grade of treatment toxicity (Fig. 3b) or
grade of neutropaenia experienced (Fig. 3c). Neither was there any
difference in pre-treatment whole-blood CDA activity between
those patients who experienced grade >3 haematological toxicity
and who did not either during the first cycle, or during the first
two cycles (Supplementary Fig. S3). After adjusting for pre-
treatment neutrophil count, baseline CDA activity did not
correlate with PFS or OS (Supplementary Table S5).
During the first cycle, CDA activity decreased incrementally
from baseline levels in both trial arms, with significantly greater
reduction at day 8 in the SEQ arm compared with the CON arm:
77% versus 47%, p < 0.0001, but this was no longer seen in the
CON arm after adjusting for neutrophil count (Supplementary
Fig. S4). However, the mean reduction from pre-treatment values
on day 15 was similar in both arms: 59% SEQ and 65% CON;
moreover, subsequent CDA activity measured on day 1, cycle 2
and during further cycles was similar to baseline levels for both
patient groups.
Tumour CDA and stroma expression
Sufficient tumour tissue from 128 patients (65 CON and 63 SEQ
arm) was available for IHC analysis. Tumour grade, CDA expression
and stroma content and their correlation with PFS and OS
associated with chemotherapy treatment are summarised in
Table 3 and Supplementary Fig. S5. When comparing the SEQ
with the CON treatment arm, strongly positive tumour epithelial
CDA staining was evident in 34 tumours and appeared to predict
for improved PFS, but not OS associated with SEQ therapy (HR
0.31, 95% CI 0.13–0.70). Eight patients whose tumours had
strongly positive CDA expression received second-line chemother-
apy on disease progression: 6 patients in the CON arm and 2
patients in the SEQ arm. In this small-size cohort, there was a trend
towards strongly positive CDA expression predicting for longer OS
with SEQ therapy (HR 0.74, 95% CI 0.36–1.56). Patients with strong
tumour CDA expression had higher whole-blood CDA activity
compared with patients with lower levels of staining (p= 0.031,
Supplementary Table S6).
Baseline tumour stromal content did not differ between the 2
trial arms. Patients whose tumours had moderate or extensive
tumour stroma staining had longer PFS and OS on nabP
+gemcitabine, irrespective of the trial arm. The unadjusted and
adjusted (for baseline characteristics of age, gender, KPS, location of
primary tumour in the pancreas, liver metastases, number of target
lesions reported, CA19.9, CRP and ANC) PFS HRs were 0.64 (95% CI
0.43–0.95) and 0.65 (95% CI 0.42–1.01), while the OS HRs were 0.63
(95% CI 0.42–0.94) and 0.52 (95% CI 0.32–0.83), respectively.
DISCUSSION
In this first, prospective randomised trial exploring alternative
scheduling of nabP with gemcitabine, SEQ delivery of nabP
+gemcitabine significantly improved PFS compared with standard
CON delivery, meeting the trial primary endpoint. However, this
did not translate into an OS benefit. Compared with the
international nabP+gemcitabine registration MPACT trial,2 the
SIEGE trial patient demographics were very similar. The ORR in the
CON arm of SIEGE (30%) and in MPACT (29% by an investigator
and 23% by an independent review) was almost identical,
although median PFS and OS in the CON arm of SIEGE (4.3 and
7.9 months) were shorter than in MPACT (5.5 and 8.5 months).
Measuring objective response and therefore PFS is notably
difficult in PDAC, so OS is recognised as a much more robust
endpoint. Although a trend for OS gain was seen, this lacked
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Response
n
Mean
CR/PR
48
12.9
SD PD
18
14.6
47
13.4
Grade of all AEs
n
Mean
1 2 3 4 5
1
9.04
10
14.6
69
13.6
38
14.9
14
15.3
Neutropaenia grade 1 2 3 4
n
Mean
6
12.3
6
8.3
39
12.5
25
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c
b
a
Fig. 3 Box-plots demonstrating that baseline (pre-treatment) cyti-
dine deaminase (CDA) activity did not predict for objec-
tive response or toxicity experienced by individual patients
during treatment. a objective response (p of Kruskal–Wallis test=
0.62), (b) worst CTCAE grade experienced (p of Kruskal–Wallis test=
0.63) and (c) worst CTCAE neutropaenia grade experienced (p of
Kruskal–Wallis test= 0.38).
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statistical significance in this non-selected patient population,
calling into question the overall clinical applicability of this novel
schedule. However, this relatively small randomised study was not
powered to show a difference in OS.
Reassuringly, despite additional hospital visit requirements, we
found no evidence that SEQ delivery generated higher levels of
non-compliance or patient withdrawals. Furthermore, patient
safety and QoL did not appear to be compromised. SEQ therapy
was associated with more treatment-related AEs, with twice the
incidence of grade ≥3 neutropaenia and use of secondary GCSF
prophylaxis, but these did not translate into loss of patient QoL
compared with CON delivery. In part, this is likely to reflect the
nature of AEs occurring, some of which were changes in blood
parameters unlikely to have immediate sequelae for patients.
Other common toxicities associated with nabP+gemcitabine did
not appear to be significantly influenced by treatment schedule.
The QoL data presented here is the most comprehensive
analysis of patient experience receiving standard CON delivery of
nabP+gemcitabine undertaken to date, which also enabled
comparison with the experimental SEQ regimen. In the MPACT
registration trial, QoL was indirectly measured using the Quality-
Adjusted Time Without Symptoms (Q-TWIST) to compare QoL and
survival associated with nabP+gemcitabine with gemcitabine
alone. Relative gains in Q-TWIST favoured the combination
regimen, ranging from 12 to 30%.12 Limited data from a phase II
study evaluating QoL with the EORTC QLQ-C30 instrument in 146
locally advanced and metastatic PDAC patients randomised to
receive either nabP+gemcitabine or gemcitabine alone have been
reported in abstract form only to date, but indicated that QoL
scores were improved and sustained with the combination
compared with gemcitabine alone.13 Our findings support these
preliminary data and go further to provide more detailed insight
into the patient experience with nabP+gemcitabine chemother-
apy. Some key findings from the patient questionnaires reported
here are of particular importance. Firstly, mean pre-treatment
QLQ-C30 global health scores were low, reflecting overall poor
QoL associated with a diagnosis of advanced PDAC.14 Global
health status scores were remarkably stable throughout treat-
ment, while the fall in QoL in the CON arm seen at 6 months might
be consistent with higher rates of patients progressing in this arm
by this time point. Secondly, the initial months of treatment were
associated with progressive loss of physical, social and role
function for patients on both arms of the trial, which persisted
over time, suggesting that chemotherapy confers considerable
interference with patients’ activities of daily living. Thirdly, the QoL
questionnaires picked out evidence of improvement in disease-
related symptoms while on treatment, in particular pain,
pancreatic pain, appetite and insomnia. These symptoms have
been previously identified as being particularly problematic for
patients with PDAC,15 suggesting that these gains may be
clinically relevant for this patient group. Other side effects known
to be associated with nabP+gemcitabine chemotherapy admin-
istration were more apparent while on treatment, in particular,
breathlessness and altered bowel habit, although these were less
problematic with SEQ compared with CON delivery.
Our clinical findings support the animal model predicting
improved efficacy of nabP+gemcitabine by exposing the cancer
to nabP in advance of gemcitabine delivery, lending weight to the
theory that nabP enhances gemcitabine cytotoxicity.6,7 The
gemcitabine-metabolising enzyme, CDA, has been implicated in
influencing patient response to treatment with gemcitabine.14,16–18
CDA is prone to genetic polymorphism, and some mutations have
been reported to influence gemcitabine exposure levels and
related toxicities.19,20 Genotyping CDA as a marker of gemcitabine
response and toxicity has been explored, while CDA functional
testing offers a simpler, easier methodology.14–16 However, after
adjustment for neutrophil count, we could not find any correlation
between whole-blood CDA activity and toxicity, or efficacy
associated with nabP+gemcitabine. Our findings reinforce those
reported in the only other prospective study evaluating CDA
activity in a cohort of 120 patients with resected PDAC who
received adjuvant gemcitabine monotherapy.17 In that study, CDA
Table 3. Summary of tumour sample immunohistochemical analyses and correlation with PFS and OS.
CON (n= 65) SEQ (n= 63) HR, 95% CI for PFS HR, 95% CI for OS
Tumour grade
Well differentiated/moderately differentiated 2 (4%)/38 (67%) 2 (4%)/38 (72%) 0.65, 0.41–1.04 0.86, 0.53–1.39
Poorly differentiated 17 (30%) 13 (24%) 0.77, 0.35–1.70 1.08, 0.50–2.33
Unknowna 8 10
Prognostic: p log rank= 0.41 (PFS), 0.12 (OS)
CDA expression—tumour epithelium
Negative/weakly positive/positive 3 (6%)/8 (15%)/ 25 (47%) 0/10 (19%)/25 (48%) 0.91, 0.56–1.48 1.07, 0.65–1.76
Strongly positive 17 (32%) 17 (33%) 0.31, 0.13–0.70 0.74, 0.36–1.56
Unknowna 12 11
Prognostic: p log rank= 0.24 (PFS), 0.88 (OS)
CDA expression—stromal cells
Weakly positive/positive 14 (34%)/22 (54%) 17 (40%)/21 (50%) 0.74, 0.46–1.20 1.10, 0.67–1.79
Strongly positive 5 (12%) 4 (10%) 0.73, 0.17–3.07 1.49, 0.33–6.81
Unknowna 24 21
Prognostic: p log rank= 0.12 (PFS), 0.48 (OS)
Presence of tumour stroma
None/minimal 11 (19%)/14 (24%) 7 (13%)/24 (45%) 0.56, 0.30–1.03 0.79, 0.45–1.38
Moderate/extensive 19 (33%)/14 (24%) 13 (24%)/9 (17%) 0.60, 0.34–1.06 0.85, 0.47–1.53
Unknowna 7 10
Prognostic: p log rank= 0.027 (PFS), 0.023 (OS)
aUnknown= insufficient tumour sample to analyse.
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activity was measured in serum,14–17 which explains the difference
in the range of CDA activity levels we have reported.21,22 The
reduction in both unadjusted and adjusted CDA activity measured
prior to day 8, cycle 1 in the SEQ arm could reflect an early signal of
altered gemcitabine metabolism associated with the enhanced
activity of SEQ administration.
Immunohistochemical studies showed that CDA staining was
identified primarily but not exclusively in the cellular compart-
ment of tumours, but only strongly positive CDA staining within
the tumour epithelial cells predicted for survival benefit with SEQ
delivery. Strong CDA expression in one-third of tumours tested
suggests that further evaluation of this potential novel biomarker
in future PDAC interventional trials may be of value.
Given the alternative hypothesis that nabP influences the
tumour stroma, we quantified stroma content in the pre-
treatment tumour biopsies. Moderate–extensive stromal content
predicted for a better outcome following nabP+gemcitabine
chemotherapy, irrespective of trial arms. PDAC is histologically
characterised by a dense stroma, which may promote tumour
growth, invasion and resistance to anticancer drug therapy,23
although recent research suggests that some elements of the
stroma may actually restrain tumour growth.24 Initial studies
suggested that nabP may exert its effect by inhibiting the stromal
protein, SPARC,2 but retrospective assessment of tumour tissue
collected from patients recruited to the MPACT trial did not
demonstrate any correlation between tumour SPARC expression
and treatment outcome.25 Genetically engineered mouse models
lacking SPARC did not result in decreased intra-tumoural nabP
concentrations or treatment efficacy,7 further placing the role of
SPARC in nabP efficacy in doubt. A better understanding of how
therapeutic interventions impact complex cancer cell–tumour
stroma interactions is clearly needed.
This feasibility trial has important limitations: it was under-
powered to detect an OS difference, while the primary endpoint,
PFS, was assessed by local investigator review, with limited central
review. Therefore, this study can only be considered hypothesis-
generating. Even so, tumour expression of key proteins implicated
in the mechanism of action of nabP+gemcitabine is of interest:
patients with more extensive tumour stroma content had longer
survival, irrespective of drug scheduling and strong intra-tumoural
CDA expression predicted for benefit from SEQ administration of
nabP+gemcitabine. These novel findings offer opportunities for
further exploration in future biomarker-driven, prospective trials
undertaken in patients with PDAC.
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